Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolcapone - Corino Therapeutics/SOM Biotech

Next Previous
Drug Profile

Tolcapone - Corino Therapeutics/SOM Biotech

Alternative Names: CRX-1008; SOM 0226

Latest Information Update: 28 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SOM Biotech
  • Developer Corino Therapeutics; SOM Biotech; Vall d-Hebron Research Institute
  • Class Antiparkinsonians; Benzophenones; Nitrophenols; Small molecules
  • Mechanism of Action Catechol O-methyltransferase inhibitors; Prealbumin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transthyretin-related hereditary amyloidosis
  • New Molecular Entity No
  • Available For Licensing Yes - Amyloid polyneuropathy

Highest Development Phases

  • Phase II Familial amyloid neuropathy
  • No development reported Transthyretin-related hereditary amyloidosis

Most Recent Events

  • 28 Nov 2021 No recent reports of development identified for phase-0 development in Transthyretin-related-hereditary-amyloidosis in USA (PO)
  • 28 Jul 2021 No recent reports of development identified for phase-I development in Familial-amyloid-neuropathy(In volunteers) in United Kingdom (PO, Tablet)
  • 15 Sep 2020 Interim efficacy and adverse events data from a phase 0 trial in transthyretin related hereditary amyloidosis released by Corino Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top